Vascular smooth muscle cells (VSMCs) are integral to the pathophysiology of cardiovascular
diseases (CVDs). Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase, plays a …

Cell reprogramming is a groundbreaking technology that, in few decades, generated a new
paradigm in biomedical science. To date we can use cell reprogramming to potentially …

Background: Direct cardiac reprogramming of fibroblasts into cardiomyocytes has emerged
as a promising strategy to remuscularize injured myocardium. However, it is insufficient to …

Directly reprogramming fibroblasts into cardiomyocytes improves cardiac function in the
infarcted heart. However, the low efficacy of this approach hinders clinical applications …

Cell fate commitment is driven by dynamic changes in chromatin architecture and activity of
lineage-specific transcription factors (TFs). The chromatin assembly factor-1 (CAF-1) is a …

Ischemic heart injury causes death of cardiomyocyte (CM), formation of a fibrotic scar, and
often adverse cardiac remodeling, resulting in chronic heart failure. Therapeutic …

The first-generation enhancer of zeste homologue 2 (EZH2) inhibitors suffer from several
limitations, such as high dosage, cofactor S-adenosylmethionine (SAM) competition, and …

Abstract Type 1 diabetes (T1D) is an autoimmune disease that selectively destroys insulin-
producing β-cells in the pancreas. An unmet need in diabetes management, current therapy …

Background Therapeutic replacement of pancreatic endocrine β-cells is key to improving
hyperglycaemia caused by insulin-dependent diabetes. Whilst the pool of ductal …

Cardiovascular diseases are the leading cause of death globally, with no cure currently.
Therefore, there is a dire need to further understand the mechanisms that arise during heart …